Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Acta Dermato-Venereologica Année : 2022

Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

E. Mahé
O. Chosidow

Résumé

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was comparison of drug survival over time. A multivariate Cox proportional hazard ratio model was computed. A total of 1,866 patients were included; 739 females (39%), median age 47 years. In the multivariate Cox model, no association was found between the calendar year of initiation and drug survival (hazard ratio) over-lapping from 0.80 (0.42–1.52) to 1.17 (0.64–2.17), p = 0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.
Fichier principal
Vignette du fichier
Bettuzzi_document.pdf (1.18 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03660920 , version 1 (31-05-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

T. Bettuzzi, H. Bachelez, M. Beylot-Barry, H. Arlégui, C. Paul, et al.. Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort. Acta Dermato-Venereologica, 2022, 102, pp.adv00665. ⟨10.2340/actadv.v101.566⟩. ⟨hal-03660920⟩
100 Consultations
37 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More